SGHT Stock Forecast: Sight Sciences, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Sight Sciences, Inc. hold a median 12-month price target of $13 — +25.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 85 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Sight Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Volatility (25): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SGHT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SGHT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +25.2% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | UBS | Maintains | Buy | $8.00 → $14 |
| 5 Nov 2026 | Piper Sandler | Reiterates | Overweight | $9.00 → $12 |
| 15 Oct 2026 | HC Wainwright & Co. | Initiates | Buy | $14 |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | $8.00 → $10 |
| 17 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 6 Aug 2026 | UBS | Maintains | Buy | $7.00 → $8.00 |
| 28 July 2026 | UBS | Assumes | Buy | $11 → $7.00 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $5.15 → $6.00 |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | UBS | Maintains | Buy | — |
| 2 Mar 2026 | Stifel | Maintains | Buy | — |
| 5 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 23 Dec 2025 | UBS | Maintains | Buy | — |
| 11 Dec 2025 | Citigroup | Maintains | Neutral | — |
| 10 Dec 2025 | Lake Street | Maintains | Buy | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 Nov 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 21 Oct 2025 | Lake Street | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SGHT.
This page is one stock. Monday covers all of them.
SGHT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SGHT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Sight Sciences, Inc. returned +53.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SGHT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 6.3×
- Price / book
- 11.3×
- EV / EBITDA
- —
Cheaper than 17% of US stocks
Cheaper than 6% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 91.4%
- Operating margin
- −20.2%
- Net margin
- −32.1%
Higher than 97% of US stocks
Higher than 22% of US stocks
Higher than 13% of US stocks
- Return on equity
- −50.1%
- Return on assets
- −10.1%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sight Sciences, Inc. has a market value of $590.2M and an enterprise value of $555.0M.
Revenue in the twelve months to 30 June 2026: $83.4M. The latest quarter grew 19.5% year on year.
Net income over the same four quarters: −$29.8M, a −35.7% net margin.
Diluted earnings per share, trailing twelve months: −$0.56.
Free cash flow in the twelve months to 30 June 2026: −$23.3M.
Sight Sciences, Inc. employs 186 people — $448K of revenue per employee.
Data provided by Twelve Data
SGHT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SGHT’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Sight Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SGHT
What is the SGHT stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Sight Sciences, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SGHT stock a buy right now?
Of the 8 analysts covering Sight Sciences, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sight Sciences, Inc. 85 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SGHT?
As at 21 Nov 2026, Sight Sciences, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
Will SGHT stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +25.2% from the last close, and Ticker Nerd's factor model ranks Sight Sciences, Inc. 85 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SGHT stock forecast for 2030?
No analyst covering Sight Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGHT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $14 over the next 12 months.
How has SGHT stock performed over the past year?
Sight Sciences, Inc. returned +53.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sight Sciences, Inc. do?
Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease. Its current product portfolio includes the OMNI Surgical System family for minimally invasive glaucoma procedures, the SION Surgical Instrument for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye associated with meibomian gland dysfunction.
About Sight Sciences, Inc.
Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease. Its current product portfolio includes the OMNI Surgical System family for minimally invasive glaucoma procedures, the SION Surgical Instrument for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye associated with meibomian gland dysfunction. The company serves eyecare providers, including ophthalmologists and optometrists, by offering tools designed to address key causes of intraocular pressure buildup and tear-film dysfunction. Sight Sciences operates through its Surgical Glaucoma and Dry Eye segments, positioning its products across procedural eyecare settings where device-based treatment options are used to support patient care. Headquartered in Menlo Park, California, Sight Sciences plays a focused role in the medical technology market by supplying specialized devices for prevalent eye conditions.
CEO Mr. Paul Badawi · 186 employees · United States · https://www.sightsciences.com